is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
24 & 25 January 2024
Paris Expo, Porte de Versailles - Hall 7.2 | Paris, France
The conference will feature thought-provoking sessions on the latest market trends and updates in the drug delivery and pharma packaging industry. Senior stakeholders from these fields are invited to attend and gain valuable insights from industry experts
Track Chair: Mayur Patel, Technology Innovation Expert, PA Consulting
This session will showcase how synergies between a small molecule formulation team, human factors, and packaging have led to better patient-centric solutions.
In addition, it will touch upon Some of the principles to consider for patient-centric development and well as well as highlight some of Roche's methods for continuous pipeline assessments to understand user needs and assign appropriate resources.
Tiffany McIntire, Principal Human Factors Engineer, Roche
This session will touch upon consumer behaviours of smart devices, their adoption and usage while measuring consumer preferences and habits around digital products and services.
The session will pose questions about which devices people have access to and how often they use them while comparing the trajectory of saturated markets like smartphones with newer markets like voice-assisted speakers and virtual reality headsets. And it speculates on our future relationship with devices amid the economic squeeze.
-Device Adoption & Usage
-Access to them
-Oversaturated & Newer Markets
Hugo Alexandre Ferreira, Associate Professor, University of Lisbon
- Besides the large multinational players, the pharmaceutical packaging market is still very fragmented
- Packaging companies face increasing size pressure from customers and suppliers-
- Regulatory and R&D requirements are increasing with a heavily rising cost base
- Are strategic alliances the right answer to these trends?
Gregor Nischer, Managing Partner, MP Corporate Finance GmbH
Patients are in need. Yet, patient involvement cannot be overcome by providing a solution that effectively and safely meets a need and is well tolerated. Patients, more concerned than ever with their health, are demanding more of such solutions. In this talk, we'll discover that if your solution meets their expectations in addition to their needs, chances are they will be more engaged with it. When that solution also helps patients to realise one or more life aspirations, the engagement in that solution becomes even more significant. These two building blocks drive customer transformation and ensure greater patient engagement with your healthcare solution.
Christophe Jauquet, Health Business Expert
- Challenges around patient digital adoption
- The need for user engagement to create meaningful solutions
- The use of digital products to improve patient experience in clinical trials
- Challenges of designing information – the use of eIFUs to create opportunities
- Packaging innovations to improve the patient experience
Charlotte Harris, Head of Front-End Innovation, Team Consulting
Ben Cox, Head of Digital Design, Team Consulting
Gabriel Lobbi, Group Head Innovation & User Experience, Connected Health Product Development, Novartis
Eva Topole, Clinical Program Leader (respiratory) and Clinical Research Physician, Chiesi
Johanna Weibel, Director, User Centred Design – Global Digital Health, Merk
Track Chair: Asmita Khanolkar, Senior Director, Cambridge Pharma/Oval, SMC Ltd.
Track Sponsor: BD
Transitioning drugs from IV to subcutaneous (SC) delivery brings new requirements and impacts program considerations for combination product development. In this session, we identify trade-offs that pharma weighs to de-risk combination product development programs involving large volume subcutaneous (LVSC) delivery. Key issues can include:
- Understanding the patient experience throughout the injection process with large volume subcutaneous delivery.
- Reducing risk of user variability to gain market confidence in successfully delivering LVSC formulations.
- Leveraging partner capabilities, insights, and data to inform combination product trade-offs and program risks.
- Manufacturability of the combination product including the delivery system and integration into the pharmaceutical operations network.
- Exploring the value of drug delivery technology used consistently from clinical development into commercial use.
- Examples of how these issues can impact a combination product development program may be explored.
Adam Kalbermatten, Vice President Commercial Development, BD Medical - Pharmaceutical Systems
This session will aim to bring together experts in the industry to discuss the trends around driving self-administration drug delivery systems and expected practices for developing an injectable combination product. Join us in this panel to discuss about:
- When is it appropriate to convert conventional injectables into autoinjectors
- Which are the advantages and disadvantages of pens and autoinjectors for chronic treatments
- eHealth and integration of electronics in medical devices: what is hindering full connectivity in pharma
- Tissue models (in-vitro / ex-vivo) for accelerating autoinjectors development
- Medical treatments in an aging world: how self-administration can improve patient adherence
- Wearable devices: state-of-the-art and next frontiers
Iain Simpson, Commercial Director - Platforms and Products, Phillips-Medisize
Mario Maio, Senior CMC Consultant, MM Pharma Consulting
Annie Zavadil, Device Project Leader, Novartis
Gurmeet Singh, Senior Director, Global Business Development, West Pharmaceutical Services
Adam Kalbermatten, Vice President Commercial Development, BD Medical - Pharmaceutical Systems
This session will highlight how robotic aseptic fill/finish equipment offers the flexibility to adjust to future growth and the speed to market necessary for today's changing industry:
- How robotics offers new answers to today's challenges
- Leveraging semi-automated to completely automated and integrated cGMP manufacturing systems for processing vials, syringes and cartridges
- Maintaining aseptic conductions throughout the production process for complex biologic compounds, recombinant proteins and monoclonal antibodies (MAbs)
Keith Dodson, Vice President of Global Business Development, AST
Biosimilar drugs offer cost-effective ground-breaking therapies to ever-expanding markets across the World. Some of these drugs are intended for self-injection using autoinjectors for enhanced usability and patient safety. Developing devices for biosimilars requires a greater focus on the cost of goods and design for manufacturing, in addition to the expected robustness, reliability and safety of a patient-centric device design.
This session will present experiences from an autoinjector development program and how to apply quality-by-design ideas to go from concept to ready for tooling in three months. Finally, we will look at the current biosimilar trends and the use of devices with biosimilars.
Charbel Tengroth, CEO, Norrneo AB
Since the introduction of the new MDR, usability engineering has been put into the focus of the lifecycle development. Especially for combination products, submissions to notified bodies require additional usability considerations and efforts.
This session will introduce attendees to important aspects that are required to comply with MDR, IEC 62366 and FDA Human factors guideline from a design and engineering perspective. The user centred design approach, incl risk aspects will also be taken into consideration.
Dorothee Weichel, Usability Expert, Helbling Technik Bern AG
Track Chair: Kristien De Clercq, Senior Senior Consultant Mechanical Engineer, Springboard Pro Ltd.
The complexity and risks found within the global pharma supply chain cannot be understated and key stakeholders from customers to regulators and investors are increasingly expecting the industry to both manage ESG risks and embed sustainability throughout the value chain. This can only be achieved through industry-wide collaboration that sets the standard for what a responsible supply chain looks like and provides support to suppliers to achieve these goals. The Pharmaceutical Supply Chain Initiative (PSCI) and our membership of 70+ pharma and healthcare companies are leading this collaboration to create harmonized approaches and frameworks for our value chains. We tackle issues such as environmental sustainability that seek to conserve natural resources, reduce greenhouse gas (GHG) emissions, preserve biodiversity and clean water and minimize and control the use of hazardous materials. A key focus of work is the challenge of decarbonization within the industry and the PSCI’s Decarbonization Maturity Model is a roadmap helping suppliers evaluate their current practices and how they can progress in line wider industry expectations.
Jose Francisco Vallejo Carrera, Global Head of Environment & Environmental Sustainability Corporate HSE, Sanofi
The pharmaceutical supply chain is complex, and pharmaceutical companies must address the most common challenges to efficiently get patients their needed medications. Despite present challenges, the supply chain is prepared to accommodate drug delivery technology in a new era of patient healthcare. This session will aim to answer some of the most pressing questions:
- Does the drug delivery industry need to be more environmentally sustainable?
- How can we or should we measure environmental impact?
- What is the current environmental impact of drug-delivery devices?
- How can we reduce environmental impact through device design?
- How can we increase environmental sustainability through supply chain optimisation?
- What could the future hold for the sustainability of the drug delivery industry?
Tom Oakley, Director of Drug Delivery Device Development, Springboard
Markus Schönfeld, Project Leader Packaging, Novartis
Claus Jürgen, Global Head of EcoDesign and Circular Economy, Sanofi
Isobel Filipova, Sustainability Lead, Owen Mumford
Julien Tremblin, General Manager Europe, TerraCycle
Nic Hunt, Sustainability Director, Nelipak
Country regulations are swiftly moving to enforce the reporting of the carbon footprint from medicinal products. A large proportion of emissions are generated from packaging and drug delivery devices, two areas that have been identified as strategic focus areas in which clear action can be taken. Healthcare systems are also pushing towards alignment across all suppliers to their net zero commitments. This is a monumental task that has ramifications across the pharmaceutical industry, not least because healthcare is far behind other sectors in understanding its carbon footprint. This session will examine the following:
- A review of the pharmaceutical industry’s carbon footprint
- Investigating the impact from drug delivery devices
- A snapshot of action from companies
- Recommendations for navigating this change in the following decade
Aurelio Arias, Engagement Manager, Thought Leadership, IQVIA
The climate crisis is, without a doubt, one of the biggest challenges for the existence of humankind. The Pharma Sector sure has quite some potential in ensuring its footprint becomes much less: The total global emissions of the Pharma Sector amounted to 52 megatonnes of CO2e (2015) – more than the automotive industry in the same year, not speaking of its potential impacts for other environmental impacts.
This presentation aims to discuss approaches to how Pharmaceutical Industry to become more sustainable and produce a carbon handprint, not a footprint.
Hanns-Christian Mahler, CEO, ten23 health
Regulations and changing customer expectations are redefining the need for pharmaceutical providers to take back used devices and packaging. These items are often made of materials not accepted in household recycling schemes. These changes drive the need to understand design for recyclability, collections and treatment and collaborations within and beyond the industry. In this session, we will explore:
- How Take-back Schemes can improve the End-of-Life Outcomes for Pharmaceutical Products and Packaging
- How Companies are Designing Innovative Schemes for their Products
- Best Practices and Lessons for Implementation
Ellen Struthers, Principal Consultant, Anthesis Group
Very impressive conference. My first time at PHARMAPACK Europe- an overall good experience and great networking opportunity. I had the opportunity to learn and see the products that interest me and my business up close, and the conference lectures were interesting, and supported the market trends I was aware of. Thank you!